Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients with Stage I Low-Risk Breast Cancer, but Fewer Breast Cancer Events
Findings from an exploratory subgroup analysis of patients included in the MINDACT study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications
Efficacy was evaluated in Inter-B-NHL Ritux 2010 global randomised study
Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not Improve Outcomes in Early Breast Cancer
The results of the final protocol-defined analysis of the PALLAS study conducted in patients with early hormone receptor-positive, HER2-negative breast cancer
FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC Melanoma
Efficacy was evaluated in KEYNOTE-716 study
Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in Terms of Invasive Disease–Free Survival
In a prespecified RxPONDER analysis, postmenopausal women with 1 to 3 positive axillary lymph nodes and a recurrence score of 0 to 25 were able to safely forgo adjuvant chemotherapy for breast cancer
Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in Low PD-L1–Expressing Gastric, Gastro-oesophageal Junction, or Oesophageal Adenocarcinoma
Retrieval of previously unreported data of PD-L1 subgroups from pivotal phase III randomised studies
p53 Mutations May Differentially Affect Survival of Patients with mCRC Based on Anatomic Location
When classified into gain-of-function and non–gain-of-function, p53 mutations could stratify the prognosis of right-sided versus left-sided metastatic colorectal cancer
FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Efficacy was evaluated in a single-arm cohort of PLEIADES study
Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP
The results from an open-label phase II study in patients with carcinoma of unknown primary
Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond Delayed CINV
The results from a head-to-head comparison of two different neurokinin-1 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced Melanoma
Longest median overall survival in a phase III melanoma study reported to date and the first report of melanoma-specific survival
FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour
Efficacy was evaluated in AMPECT study in patients with locally advanced unresectable or metastatic malignant PEComa